| Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles W Li, A Asokan, Z Wu, T Van Dyke, N DiPrimio, JS Johnson, ... Molecular Therapy 16 (7), 1252-1260, 2008 | 300 | 2008 |
| Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle A Asokan, JC Conway, JL Phillips, C Li, J Hegge, R Sinnott, S Yadav, ... Nature biotechnology 28 (1), 79-82, 2010 | 277 | 2010 |
| Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles C Li, N Diprimio, DE Bowles, ML Hirsch, PE Monahan, A Asokan, ... Journal of virology 86 (15), 7752-7759, 2012 | 117 | 2012 |
| Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction JS Johnson, C Li, N DiPrimio, MS Weinberg, TJ McCown, RJ Samulski Journal of virology 84 (17), 8888-8902, 2010 | 115 | 2010 |
| Surface loop dynamics in adeno-associated virus capsid assembly N DiPrimio, A Asokan, L Govindasamy, M Agbandje-McKenna, ... Journal of virology 82 (11), 5178-5189, 2008 | 86 | 2008 |
| Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG S Iyer, FS Sam, N DiPrimio, G Preston, J Verheijen, K Murthy, Z Parton, ... Disease models & mechanisms 12 (11), dmm040584, 2019 | 67 | 2019 |
| Methods and compositions for adeno-associated virus (aav) with hi loop mutations N Diprimio, RJ Samulski US Patent App. 12/369,945, 2009 | 61 | 2009 |
| Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo C Li, M Hirsch, N DiPrimio, A Asokan, K Goudy, R Tisch, RJ Samulski Journal of virology 83 (13), 6817-6824, 2009 | 52 | 2009 |
| The designability of protein switches by chemical rescue of structure: mechanisms of inactivation and reactivation Y Xia, N DiPrimio, TR Keppel, B Vo, K Fraser, KP Battaile, C Egan, ... Journal of the American Chemical Society 135 (50), 18840-18849, 2013 | 41 | 2013 |
| Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. N DiPrimio, SW McPhee, RJ Samulski Current opinion in molecular therapeutics 12 (5), 553-560, 2010 | 40 | 2010 |
| Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches S Iyer, JD Mast, H Tsang, TP Rodriguez, N DiPrimio, M Prangley, FS Sam, ... Disease Models & Mechanisms 12 (11), dmm040576, 2019 | 26 | 2019 |
| Yeast models of phosphomannomutase 2 deficiency, a congenital disorder of glycosylation JP Lao, N DiPrimio, M Prangley, FS Sam, JD Mast, EO Perlstein G3: Genes, Genomes, Genetics 9 (2), 413-423, 2019 | 17 | 2019 |
| GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts EA Granatosky, N DiPrimio, JRE Pickering, DC Stevens, EO Perlstein, ... Journal of natural products 81 (9), 2018-2025, 2018 | 9 | 2018 |
| Methods for treating congenital disorders of glycosylation EO Perlstein, J Lao, F Sam, N Diprimio, Z Parton, H Tsang, K Murthy, ... US Patent 11,160,794, 2021 | 1 | 2021 |
| Surface Loop Dynamics of a Parvovirus N DiPrimio | 1 | 2009 |
| Methods for treating congenital disorders of glycosylation EO Perlstein, J Lao, F Sam, N Diprimio, Z Parton, H Tsang, K Murthy, ... US Patent App. 17/489,149, 2022 | | 2022 |
| Multi-Species Phenotypic Screening across Disease Models of Mucolipidosis Type IV A Hadjikyriacou, S Iyer, JD Mast, N DiPrimio, J Concannon, J Ketterman, ... BioRxiv, 2021.03. 05.434120, 2021 | | 2021 |
| 104. Role of the HI Loop in the Adeno-Associated Virus (AAV) Life Cycle. N DiPrimio, A Asokan, RJ Samulski Molecular Therapy 13, 2006 | | 2006 |
